×

Pfizer deal 'wounded,' not dead: Analyst

12:15 PM ET Mon, 19 May 2014

AstraZeneca told Pfizer its final offer isn't good enough. Mark Schoenebaum, ISI Group biotech & pharma analyst, provides insight to the potential deal.